Abstract Changes in DNA methylation in cancer have been heralded as promising targets
for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite …

Current tendencies in the treatment course of prostate cancer patients increase the need for
reliable biomarkers that help in decision-making in a challenging clinical setting. Within the …

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …

Purpose: The DOCUMENT multicenter trial in the United States validated the performance of
an epigenetic test as an independent predictor of prostate cancer risk to guide decision …

Purpose: Concern about possible false-negative prostate biopsy histopathology findings
often leads to rebiopsy. A quantitative methylation specific polymerase chain reaction assay …

In the era of upcoming techniques for molecular profiling, breakthroughs led to new
discoveries in the field of prostate cancer (PCa) biomarkers. Since the early 1990s a …

Purpose Diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, causing
overtreatment of indolent PC and risk of delayed treatment of aggressive PC. Here, we …

Lung cancer is indeed a major cause of cancer‐related deaths worldwide. The development
of tumors involves a complex interplay of genetic, epigenetic, and environmental factors …

Introduction: Prostate cancer is a common malignancy with highly variable clinical
presentation and outcomes. Diagnosis and management remain a challenge and at times …

Prostate cancer (PC) is the most commonly diagnosed neoplasm and the third most
common cause of cancer-related death amongst men in the Western world. PC is a clinically …